publicações selecionadas
-
artigo académico
- In vitro and in vivo evaluation of novel chromeno[2,3-d]pyrimidinones as therapeutic agents for triple negative breast cancer. RSC Medicinal Chemistry. 2024
- Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of Spinocerebellar ataxia type 3. Journal of Clinical Investigation. 2024
- Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of Spinocerebellar ataxia type 3 (IF: 19.47). The Journal of Clinical Investigation. 2024
- Transition from Animal-Based to Human Induced Pluripotent Stem Cells (iPSCs)-Based Models of Neurodevelopmental Disorders: Opportunities and Challenges. Cells. 2023
- Synthesis and Biological Evaluation of Novel Chromeno[2,3-d]Pyrimidinones as Agents for Triple Negative Breast Cancer Treatment. European Journal of Medicinal Chemistry (IF 7.08, Q1 Chemistry, Organic). 2023
- Chronic pain causes Tau-mediated hippocampal pathology and memory deficits. Elife. 2022
- Integration of behavior and neuronal physiology in a mouse model of Rett Syndrome: a focus on serotonergic system modulation. Journal of Neurochemistry. 2022
-
artigo de conferência
-
artigo de revista
-
documento
- Characterization of the movement disorder phenotype of a mouse model of Down Syndrome 2024
- In vitro and in vivo evaluation of novel chromeno[2,3-d]pyrimidinones as therapeutic agents for triple negative breast cancer 2023
- Avaliação in vitro e in vivo de novos cromeno[2,3-d]pirimidinonas como agentes terapêuticos para o cancro da mama triplo-negativo 2023
- Limited Therapeutic Impact of Intermittent Fasting and Ketogenic diets in a Mouse Model of Spinocerebellar Ataxia Type 3 2023
- Assessing the HPA-axis mediated stress responses in a mouse model of SCA3 2023
- Motor coordination and balance ameliorated after treatment of the CMVMJD135 mouse model of Spinocerebellar Ataxia Type 3 with befiradol 2022
- Motor coordination and balance ameliorated after treatment of the CMVMJD135 mouse model of Spinocerebellar Ataxia Type 3 with befiradol 2022
- Understanding the relevance of the cerebellar cognitive affective syndrome in SCA3 mice 2022
- The study of depression and cognitive comorbidities in a mouse model of spinocerebellar ataxia type 3 2022
- Pre and post-symptomatic treatment with NLX-112 improved the balance and motor coordination of the CMVMJD135 mouse model of Machado-Joseph Disease 2022
- Pre and post-symptomatic treatment with NLX-112 improved the balance and motor coordination of the CMVMJD135 mouse model of Machado-Joseph Disease 2022
- Stress resilience in SCA3: study of depression and cognitive comorbidities in a mouse model 2022
- Preclinical study of a 5-HT1A receptor specific agonist in the CMVMJD135 mouse model of Machado-Joseph disease 2022
- Can chronic activation of serotonergic signalling be a therapeutic approach for neurodegenerative diseases? 2021
- Can chronic activation of serotonergic signalling be atherapeutic approach for neurodegenerative diseases? 2021
- NLX-112 improved the motor coordination and balance in a Mouse Experimental Model of Machado-Joseph Disease 2021
- Does activation of serotonergic treatment suppress proteotoxicity in mouse models of neurodegenerative diseases? 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Disorders 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Diseases 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Diseases 2020
- A novel role for Tau protein in the mechanisms of brain damage caused by peripheral neuropathy 2018
- A novel role for tau protein in the mechanisms of brain damage caused by peripheral neuropathy. Eur Neuropsychopharmacol 2018; 28:S56. 2018
- A novel role for Tau protein in mood and cognitive deficits induced by a peripheral neuropathy 2017
- A novel role for Tau protein in the mood and cognitive deficits triggered by peripheral neuropathy 2017
-
teses